CA2450961C — Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2010-03-30 · 16y expired
What this patent protects
The invention relates to crystalline, water-free (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane-bromide, to a method for its production, and to the use thereof in the production of a drug, espe…
USPTO Abstract
The invention relates to crystalline, water-free (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane-bromide, to a method for its production, and to the use thereof in the production of a drug, especially in the production of an anticholinergic drug.
Drugs covered by this patent
- Alunbrig (brigatinib) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.